苗族与东亚人群重要药物基因等位基因频率差异的潜在临床意义
该研究基于社区参与式行动研究,分析194名美国苗族成人8个重要药物基因的22个变异等位基因频率,并与东亚人群已发表数据比较。发现23%(5/22)的CPIC可操作变异频率存在显著差异,影响华法林、辛伐他汀和苯妥英的预测用药推荐。
要点
- 苗族与东亚人群在CYP2C9*3A、CYP2C19*2、CYP2C19*3、CYP4F2*3和SLCO1B1*5频率上差异显著
- 这些差异显著影响华法林、辛伐他汀和苯妥英的CPIC预测用药推荐
- 临床为苗族患者选择药物和剂量时不应直接套用东亚人群数据
核心结论
- 苗族与东亚人群在影响药物选择和剂量的关键基因变异频率上存在重要差异。
- 这些差异的幅度和性质预期会导致苗族相对于东亚人群的不同用药推荐。
研究设计与样本
- 采用社区参与式行动研究方法,分析194名居住在美国的苗族成人的DNA。
- 检测8个重要药物基因(CYP2C9、CYP2C19、CYP4F2、DPYD、G6PD、SLCO1B1、TPMT、VKORC1)的22个遗传变异。
- 将苗族参与者的等位基因频率及基于CPIC指南的预测用药需求与东亚人群已发表数据进行比较。
主要发现
- 22个CPIC可操作变异中有23%(5/22)在苗族与东亚人群间等位基因频率存在显著差异。
- CYP2C9*3A频率苗族16.6% vs 东亚3.4%。
- CYP2C19*2频率苗族42.2% vs 东亚29.0%。
- CYP2C19*3频率苗族0.3% vs 东亚8.3%。
- CYP4F2*3频率苗族6.5% vs 东亚22.1%;SLCO1B1*5频率苗族3.6% vs 东亚0.1%。
关键数值与推荐
- CYP2C9*3A等位基因频率:苗族16.6%,东亚3.4%。
- CYP2C19*2等位基因频率:苗族42.2%,东亚29.0%。
- CYP2C19*3等位基因频率:苗族0.3%,东亚8.3%。
- CYP4F2*3等位基因频率:苗族6.5%,东亚22.1%。
- SLCO1B1*5等位基因频率:苗族3.6%,东亚0.1%。
临床怎么用
- 为苗族患者进行药物基因检测结果解读时,应参考苗族人群特异性等位基因频率数据。
- 使用CPIC指南预测华法林、辛伐他汀和苯妥英的用药推荐时,苗族与东亚人群可能存在差异。
- 不应将东亚人群的等位基因频率数据直接外推至苗族患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Implementing pharmacogenetics for very important pharmacogenes (VIPs) holds the promise of improving clinical outcomes through optimal medication selection and dosing. However, significant differences in the frequency of actionable variants in VIPs may exist within subpopulations of a given ancestral group. Furthermore, these differences can potentially impact drug selection and dosing. The purpose of this study was to ascertain allele frequencies for VIPs and to predict medication requirements using Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines in Hmong and compare with published data for East Asians. METHODS: Using a community-based participatory action research approach, DNA collected from 194 Hmong adults living in the United States was analyzed for 22 genetic variants within eight VIPs (CYP2C9, CYP2C19, CYP4F2, DPYD, G6PD, SLCO1B1, TPMT, VKORC1). Allele frequencies for VIPs and predicted medication requirements using CPIC guidelines were compared between Hmong participants and East Asians. RESULTS: Significant differences in allele frequencies between the Hmong and East Asians were found for 23% (5/22) of the CPIC-actionable variants tested. Allele frequencies for VIPs in Hmong versus East Asians were 16.6% versus 3.4% in CYP2C9*3A, 42.2% versus 29.0% for CYP2C19*2, 0.3% versus 8.3% in CYP2C19*3, 6.5% versus 22.1% in CYP4F2*3, and 3.6% versus 0.1% in SLCO1B1*5, respectively. These differences significantly influenced predicted medication usage recommendations in warfarin, simvastatin, and phenytoin between Hmong and East Asians. CONCLUSIONS: Important differences in allele frequencies for key genetic variants influencing selection of medications and dosages were found between the Hmong and East Asians. The magnitude and nature of these differences can be expected to result in different medication recommendations for the Hmong relative to East Asians.
引用
- Wen YF, Culhane-Pera KA, Thyagarajan B, et al. Potential Clinical Relevance of Differences in Allele Frequencies Found within Very Important Pharmacogenes between Hmong and East Asian Populations. Pharmacotherapy. 2020. PMID: 31884695. doi:10.1002/phar.2360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。